CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has been effective conscientiously but unsuccessfully to create an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be being used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past several shares. My 1st CytoDyn article, “CytoDyn: What to be able to Do When It is Too Good To Be True?”, set away the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a very marketing image in the Uptick Newswire employment interview that I came away with a poor opinion of the company.

Irony of irony, the bad viewpoint of mine of the business has grown steadily, although the disappointment hasn’t been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger yet still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your therapy and prevention of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this technology as well as connected intellectual property coming from Progenics to CytoDyn, and also approximately 25 million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 million) as well as the first new drug application endorsement ($5 million), and even royalty payments of 5 percent of net sales after commercialization.

Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many therapies and numerous indications, it’s this single treatments in addition to a “broad pipeline of indications” because it places it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an energetic organization with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple presentations and multiple publications.

Can it all be smoke and mirrors? That is a question I’ve been asking myself with the really beginning of my interest in this particular company. Judging by the multiples of thousands of diverse responses on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this question.

CytoDyn is a traditional battleground, or perhaps some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

This entry was posted in Health. Bookmark the permalink.